(PharmaNewsWire.Com, January 11, 2017 ) Biosimilars are defined as the follow-on versions of original biological medicines. These are separately developed after the patent protecting the original product has expired. Biosimilars are intended to have the same MOA as original biological drugs and are designed to treat the same diseases as the innovator's product. They have many similarities, but are not identical to, the reference biopharmaceutical product.
Publisher's analysts forecast the global biosimilars market to grow at a CAGR of 55.52% during the period 2016-2020. For more information about this report: http://www.reportsweb.com/global-biosimilars-market-2016-2020 Covered in this report The report covers the present scenario and the growth prospects of the global biosimilars market for 2016-2020. To calculate the market size, the report considers the revenue generated from the sale of products such as somatropin, erythropoietin, colony-stimulating factors (CSF), interferons, interleukins, insulin and insulin analogs, follicle stimulating hormones (FSH), monoclonal antibodies (mAbs), and low molecular weight heparins (LMWH).
The market is divided into the following segments based on geography: - Americas - APAC - EMEA
Publisher's report, Global Biosimilars Market 2016-2020, has been prepared based on an in-depth market analysis with inputs from industry experts. The report covers the market landscape and its growth prospects over the coming years. The report also includes a discussion of the key vendors operating in this market.
We are pleased to offer you this exciting, new, and entirely free professional resource. Visit our Free Biotechnology & Pharmaceuticals resource center today to browse our selection of 600+ complimentary Biotechnology & Pharmaceuticals magazines, white papers, webinars, podcasts, and more. Get popular titles including: